hLab offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy.hLab offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy.
Effective concentration 50% (EC50) (TCID50 and plaque reduction) determination for candidate antivirals against Coronavirus alpha and beta (OC43, 229E, SARS-CoV2), RSV A & B and FLU (H3N2 & H1N1) viruses
Comparison to medically relevant antiviral compounds available commercially
Compound efficacy against hVIVO GMP challenge viruses and a wide range of other relevant related viruses to inform study design
Shifts in compound efficacy assessed by EC50 and Next Generation Sequencing (NGS) for phenotypic and genotypic (variant analyses) antiviral resistance monitoring
